首页|醒脑静注射液辅助急诊溶栓抗凝治疗急性脑梗塞的临床效果分析

醒脑静注射液辅助急诊溶栓抗凝治疗急性脑梗塞的临床效果分析

扫码查看
目的 探究急性脑梗塞的急诊溶栓抗凝治疗中,辅助应用醒脑静注射液的价值.方法 研究选取南阳市中心医院 2022 年 6 月至 2023 年 12 月期间收入的 90 例急性脑梗塞患者,通过随机原则,将其分为研究组(n=45,急诊溶栓抗凝治疗+醒脑静注射液)、对照组(n=45,急诊溶栓抗凝治疗),分析其在溶栓效果、临床疗效、预后情况、血清指标以及不良反应方面的差异.结果 治疗前,两组美国国立卫生研究院卒中量表(NIHSS)评分比较差异无统计学意义(P>0.05);治疗 14 d后,两组NIHSS评分均降低,且研究组低于对照组,差异均有统计学意义(P<0.05);研究组治疗有效率(93.33%)高于对照组(77.78%),差异具有统计学意义(P<0.05);治疗前,两组改良Rankin评分量表(mRS)评分比较,差异无统计学意义(P>0.05);治疗 14 d后,两组mRS评分均降低,且研究组低于对照组,差异均有统计学意义(P<0.05);治疗前,两组同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)水平比较,差异无统计学意义(P>0.05),治疗后,两组Hcy、hs-CRP水平均降低,且研究组低于对照组,差异均有统计学意义(P<0.05).治疗后,两组不良反应发生率比较,差异无明显统计学意义(P>0.05).结论 急性脑梗塞的急诊溶栓抗凝治疗中辅助应用醒脑静注射液能够改善神经功能、提高治疗有效率、起到抗炎与改善预后的作用,具有临床应用意义.
Analysis of Xingnaojing Injection Assisting Emergency Thrombolysis and Anticoagulation Treatment in Acute Cerebral Infarction
Objective To explore the value of auxiliary application of Xingnaojing injection in emergency thrombolysis and anticoagulation treatment for acute cerebral infarction.Methods The study selected 90 patients with acute cerebral infarction admitted to Nanyang Central Hospital from June 2022 to December 2023.They were randomly assigned to a study group(n=45,emergency thrombolysis and anticoagulation treatment+Xingnaojing injection)and a control group(n=45,emergency thrombolysis and anticoagulation treatment).The differences in thrombolytic effect,clinical efficacy,prognosis,serum indicators,and adverse reactions were analyzed.Results Before treatment,there was no significant difference in the National Institutes of Health Stroke Scale(NIHSS)scores between the two groups(P>0.05).After 14 days of treatment,NIHSS scores decreased in both groups,with the study group showing significantly lower scores than the control group(P<0.05).The effective treatment rate in the study group(93.33%)was higher than that in the control group(77.78%),showing a statistically significant difference(P<0.05).Prior to treatment,There was no statistically significant difference in the modified Rankin Rating Scale(mRS)scores between the two groups(P>0.05).After 14 days,mRS scores decreased in both groups,with the study group having lower scores than the control group the difference was statistically significant(P<0.05).There were no significant differences in levels of homocysteine(Hcy)and high-sensitivity C-reactive protein(hs-CRP)between the two groups prior to treatment(P>0.05).After treatment,levels of Hcy and hs-CRP decreased in both groups,with the study group exhibiting lower levels than the control group the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups after treatment(P>0.05).Conclusion The auxiliary application of Xingnaojing injection in emergency thrombolysis and anticoagulation treatment for acute cerebral infarction can improve neurological function,increase the effective treatment rate,exert anti-inflammatory effects,and improve prognosis,demonstrating clinical significance.

Xingnaojing injectionemergencythrombolysis and anticoagulation treatmentacute cerebral infarctionefficacy

夏新艳、张丹丹

展开 >

南阳市中心医院 神经重症二病区,河南 南阳 473000

醒脑静注射液 急诊 溶栓抗凝治疗 急性脑梗塞 疗效

2024

临床研究
西安交通大学

临床研究

影响因子:0.234
ISSN:2096-1278
年,卷(期):2024.32(12)